Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA Consortium

(1) Background: molecular tumor boards (MTBs) are crucial instruments for discussing and allocating targeted therapies to suitable cancer patients based on genetic findings. Currently, limited evidence is available regarding the regional impact and the outreach component of MTBs; (2) Methods: we analyzed MTB patient data from four neighboring Bavarian tertiary care oncology centers in Würzburg, Erlangen, Regensburg, and Augsburg, together constituting the WERA Alliance. Absolute patient numbers and regional distribution across the WERA-wide catchment area were weighted with local population densities; (3) Results: the highest MTB patient numbers were found close to the four cancer centers. However, peaks in absolute patient numbers were also detected in more distant and rural areas. Moreover, weighting absolute numbers with local population density allowed for identifying so-called white spots-regions within our catchment that were relatively underrepresented in WERA MTBs; (4) Conclusions: investigating patient data from four neighboring cancer centers, we comprehensively assessed the regional impact of our MTBs. The results confirmed the success of existing collaborative structures with our regional partners. Additionally, our results help identifying potential white spots in providing precision oncology and help establishing a joint WERA-wide outreach strategy.

Citing Articles

A prospective pragmatic evaluation of automatic trial matching tools in a molecular tumor board.

Gueguen L, Olgiati L, Brutti-Mairesse C, Sans A, Le Texier V, Verlingue L NPJ Precis Oncol. 2025; 9(1):28.

PMID: 39870746 PMC: 11772588. DOI: 10.1038/s41698-025-00806-y.

Empowering personalized oncology: evolution of digital support and visualization tools for molecular tumor boards.

Strantz C, Bohm D, Ganslandt T, Borries M, Metzger P, Pauli T BMC Med Inform Decis Mak. 2025; 25(1):29.

PMID: 39819625 PMC: 11736948. DOI: 10.1186/s12911-024-02821-8.

Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch.

Deschler-Baier B, Krebs M, Kroiss M, Chatterjee M, Gundel D, Kestler C NPJ Precis Oncol. 2024; 8(1):167.

PMID: 39085487 PMC: 11291676. DOI: 10.1038/s41698-024-00659-x.

The Concept of Stroma AReactive Invasion Front Areas (SARIFA) as a new prognostic biomarker for lipid-driven cancers holds true in pancreatic ductal adenocarcinoma.

Grochowski P, Grosser B, Sommer F, Probst A, Waidhauser J, Schenkirsch G BMC Cancer. 2024; 24(1):768.

PMID: 38926671 PMC: 11210040. DOI: 10.1186/s12885-024-12519-9.

Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center.

Togel L, Schubart C, Lettmaier S, Neufert C, Hoyer J, Wolff K Cancers (Basel). 2023; 15(24).

PMID: 38136436 PMC: 10741918. DOI: 10.3390/cancers15245892.

References

Polite B, Adams-Campbell L, Brawley O, Bickell N, Carethers J, Flowers C . Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. J Clin Oncol. 2017; 35(26):3075-3082. DOI: 10.1200/JCO.2017.73.6546. View

Pishvaian M, Blais E, Bender R, Rao S, Boca S, Chung V . A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. JAMIA Open. 2020; 2(4):505-515. PMC: 6994017. DOI: 10.1093/jamiaopen/ooz045. View

Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hullein J . Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discov. 2021; 11(11):2780-2795. DOI: 10.1158/2159-8290.CD-21-0126. View

Ebi H, Bando H . Precision Oncology and the Universal Health Coverage System in Japan. JCO Precis Oncol. 2020; 3. PMC: 7446489. DOI: 10.1200/PO.19.00291. View

Bellaiche M, Fan W, Walbert H, McClave E, Goodnight B, Sieling F . Disparity in Access to Oncology Precision Care: A Geospatial Analysis of Driving Distances to Genetic Counselors in the U.S. Front Oncol. 2021; 11:689927. PMC: 8242948. DOI: 10.3389/fonc.2021.689927. View

Takeda M, Sakai K, Takahama T, Fukuoka K, Nakagawa K, Nishio K . New Era for Next-Generation Sequencing in Japan. Cancers (Basel). 2019; 11(6). PMC: 6627271. DOI: 10.3390/cancers11060742. View

Afshar N, English D, Milne R . Rural-urban residence and cancer survival in high-income countries: A systematic review. Cancer. 2019; 125(13):2172-2184. DOI: 10.1002/cncr.32073. View

Luchini C, Lawlor R, Milella M, Scarpa A . Molecular Tumor Boards in Clinical Practice. Trends Cancer. 2020; 6(9):738-744. DOI: 10.1016/j.trecan.2020.05.008. View

Buechner P, Hinderer M, Unberath P, Metzger P, Boeker M, Acker T . Requirements Analysis and Specification for a Molecular Tumor Board Platform Based on cBioPortal. Diagnostics (Basel). 2020; 10(2). PMC: 7167859. DOI: 10.3390/diagnostics10020093. View

10.

Tamborero D, Dienstmann R, Rachid M, Boekel J, Baird R, Brana I . Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nat Med. 2020; 26(7):992-994. DOI: 10.1038/s41591-020-0969-2. View

11.

Tan A, Tan D . Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol. 2022; 40(6):611-625. DOI: 10.1200/JCO.21.01626. View

12.

Popejoy A, Fullerton S . Genomics is failing on diversity. Nature. 2016; 538(7624):161-164. PMC: 5089703. DOI: 10.1038/538161a. View

13.

Sultova E, Westphalen C, Jung A, Kumbrink J, Kirchner T, Mayr D . Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting. Diagnostics (Basel). 2021; 11(4). PMC: 8074310. DOI: 10.3390/diagnostics11040733. View

14.

Burkard M, Deming D, Parsons B, Kenny P, Schuh M, Leal T . Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. JCO Precis Oncol. 2020; 1. PMC: 7450916. DOI: 10.1200/PO.16.00022. View

15.

Tasken K, Russnes H, Aas E, Bjorge L, Blix E, Enerly E . A national precision cancer medicine implementation initiative for Norway. Nat Med. 2022; 28(5):885-887. DOI: 10.1038/s41591-022-01777-4. View

16.

van der Velden D, van Herpen C, van Laarhoven H, Smit E, Groen H, Willems S . Molecular Tumor Boards: current practice and future needs. Ann Oncol. 2017; 28(12):3070-3075. DOI: 10.1093/annonc/mdx528. View

17.

Huey R, Hawk E, Offodile 2nd A . Mind the Gap: Precision Oncology and Its Potential to Widen Disparities. J Oncol Pract. 2019; 15(6):301-304. DOI: 10.1200/JOP.19.00102. View

18.

Hoefflin R, Lazarou A, Hess M, Reiser M, Wehrle J, Metzger P . Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. Cancers (Basel). 2021; 13(5). PMC: 7962829. DOI: 10.3390/cancers13051151. View

19.

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

20.

Kato S, Kim K, Lim H, Boichard A, Nikanjam M, Weihe E . Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020; 11(1):4965. PMC: 7532150. DOI: 10.1038/s41467-020-18613-3. View